Asia Pacific Pharmacokinetics Services Market Forecast to 2031 - Regional Analysis - by Drug Type, Service Type, Therapeutic Application, and End User
상품코드:1597064
리서치사:The Insight Partners
발행일:2024년 10월
페이지 정보:영문 95 Pages
라이선스 & 가격 (부가세 별도)
한글목차
아시아태평양의 약동학 서비스 시장은 2023년에 1억 9,144만 달러로 평가되었고, 2031년에는 3억 5,658만 달러에 이를 것으로 예측되며, 2023년부터 2031년까지 8.1%의 연평균 복합 성장률(CAGR)을 나타낼 것으로 추정됩니다.
약물동태의 변동을 이해하기 위한 생체내 모델 및 생체외 모델의 채용이 증가하여 아시아태평양의 약물동태 서비스 시장을 촉진
의약품 제조시 발생하는 방대한 약동학 데이터의 수집과 처리는 고가이고 번거롭고 시간이 많이 걸리는 작업입니다. in vitro-in vivo 약동학 상관 모델(IVIVC) 등의 모델의 필요성이 부각되어 있습니다. 약동학 시뮬레이션 모델은 계산 및 수학적 모델을 사용하여 특정 조건 하에서의 생활 환경에서의 약동학을 해석하는 도구입니다. 의약품 개발의 초기 단계에서 PK/PD 예측을 분석하는 것은 리드 화합물의 최적화 전략에 필요하며 또한 감소율을 추가로 줄이기 위해 필요합니다. 입니다 약동학 특성을 개선하고 특 징징을 위한 새로운 in-vitro 및 in-vivo 전략의 개발에서 현저한 진보가 보입니다. 따라서 비용 효율적인 대안으로 제안되었습니다. 따라서 이러한 in-vivo 및 in-vitro 모델은 가까운 미래에 아시아태평양 약물 동태 서비스 시장에 유리한 기회를 제공할 것으로 예상됩니다.
아시아태평양의 약동학 서비스 시장 개요
중국에서 아시아태평양 약물동태 서비스 시장의 성장은 주로 확립된 의약품 시장, 제약·바이오 의약품 기업에 의한 연구 개발비 증가, 운영 비용의 저하에 의한 임상시험 건수 증가, 유리한 규제 정책의 실시 에 기인합니다. 2023년에 발표된 EFPIA 보고서에 따르면 중국 제약 회사 에 의한 연구 개발비는 2020년의 108억 1,423만 달러에서 2021년에는 129억 8,923만 달러로 증가했습니다. 중국은 세계 제2위의 의약품 시장입니다. 전염성 질환과 감염 증가는 신약 분자의 필요성을 부추겨 중국을 아시아태평양의 주요 시장으로 만들고 있습니다.
아시아태평양의 약동학 서비스 시장 수익과 2031년까지의 예측(단위: 100만 달러)
아시아태평양 약동학 서비스 시장 내역
아시아태평양의 약동학 서비스 시장은 약물 유형별, 서비스 유형별, 치료 용도별, 최종 사용자별, 국가별로 분류됩니다.
약물 유형별로 아시아태평양의 약동학 서비스 시장은 저분자, 고분자 및 백신으로 나뉩니다.
서비스 유형별로 아시아태평양의 약동학 서비스 시장은 전임상 ADME 및 인간 시험, PK/PD 분석 및 보고, 투여 시뮬레이션, 위험 분석 등으로 분류됩니다. 테스트 부문이 가장 큰 시장 점유율을 차지합니다.
치료 용도별로 아시아태평양의 약동학 서비스 시장은 암, 감염증, 신경질환, 자가면역질환, 부인과질환, 심혈관질환, 호흡기질환 등으로 구분됩니다. 암 영역이 가장 큰 시장 점유율을 차지합니다.
최종 사용자별로 아시아태평양의 약동학 서비스 시장은 제약·바이오테크놀러지 기업, CRO, 기타로 구분됩니다.
국가별로 아시아태평양의 약동학 서비스 시장은 중국, 일본, 인도, 호주, 한국 및 기타 아시아태평양 국가로 구분됩니다.
Allucent, Certara Inc., Charles River Laboratories International Inc, Eurofins Scientific SE, PACIFIC BIOLABS, Parexel International Corp, SGS SA, Shanghai Medicilon Inc, Thermo Fisher Scientific Inc. 등이 아시아태평양의 약동학 서비스 시장에서 사업을 전개 주요 기업입니다.
목차
제1장 서론
제2장 주요 요약
제3장 조사 방법
제4장 아시아태평양의 약동학 서비스 시장 : 주요 시장 역학
시장 성장 촉진요인
만성 질환·감염증의 유병률의 상승
약동학 연구에의 응용 범위의 확대
CRO에 대한 약동학 서비스의 아웃소싱
시장 성장 억제요인
신흥국에서의 약동학 서비스 업자의 리치의 제약
시장 기회
약물동태의 편차를 이해하기 위한 생체내·생체외 모델의 채용 증가
향후의 동향
약동학 서비스에서 빅데이터 분석 채용 증가
성장 촉진요인과 저해요인의 영향
제5장 아시아태평양의 약동학 서비스 시장 분석
아시아태평양의 약동학 서비스 시장 개요
아시아태평양의 약동학 서비스 시장의 수익(2021-2031년)
제6장 아시아태평양의 약동학 서비스 시장 분석 : 약제 유형별
저분자
대형 분자
백신
제7장 아시아태평양의 약동학 서비스 시장 분석 : 서비스 유형별
전임상 ADME 및 인간 시험
PK/PD 분석과 리포팅
투여 시뮬레이션
리스크 분석
기타
제8장 아시아태평양의 약동학 서비스 시장 분석 : 치료 용도별
암 영역
감염증
신경질환
자가면역질환
부인과 질환
순환기 질환
호흡기 질환
기타
제9장 아시아태평양의 약동학 서비스 시장 분석 : 최종 사용자별
제약·바이오테크놀러지 기업
CRO(의약품 개발 업무 수탁 기관)
기타
제10장 아시아태평양의 약동학 서비스 시장 : 국가별 분석
아시아태평양
중국
일본
인도
호주
한국
기타 아시아태평양 국가
제11장 기업 프로파일
Charles River Laboratories International Inc
Eurofins Scientific SE
Certara Inc.
Parexel International Corp
Thermo Fisher Scientific Inc.
Allucent
PACIFIC BIOLABS
SGS SA
Shanghai Medicilon Inc.
제12장 부록
JHS
영문 목차
영문목차
The Asia Pacific pharmacokinetics services market was valued at US$ 191.44 million in 2023 and is expected to reach US$ 356.58 million by 2031; it is estimated to register a CAGR of 8.1% from 2023 to 2031.
Increasing Adoption of In-Vivo and In-Vitro Models for Understanding Variability in Pharmacokinetics Boost Asia Pacific Pharmacokinetics Services Market
The collection and handling of huge pharmacokinetic data generated during drug manufacturing are expensive, tedious, and time-consuming tasks. The labor- and cost-intensive nature of these tasks highlights the need for models such as pharmacokinetic simulation models and in vitro-in vivo pharmacokinetic correlation models (IVIVC) for the prediction of pharmacokinetic parameters. The pharmacokinetic simulation model is a tool that interprets drug kinetics in the living environment under specific conditions using computational and mathematical models. In addition, the IVIVC model are a fundamental part of the drug discovery process. Analyzing PK/PD predictions at the early stages of drug development is necessary for lead optimization strategies and also to further reduce attrition rates. There have been significant advancements in the development of new in-vitro and in-vivo strategies to improve and characterize pharmacokinetic properties. IVIVC models are being proposed as a cost-effective alternative to assess the biopharmaceutical properties that analyze the bioavailability of drugs and their application. Hence, such in-vivo and in-vitro models are anticipated to provide lucrative opportunities for the Asia Pacific pharmacokinetics services market in the near future.
Asia Pacific Pharmacokinetics Services Market Overview
The Asia Pacific pharmacokinetics services market growth in China is primarily attributed to the established pharmaceutical market, increasing R&D expenditures by pharmaceutical and biopharmaceutical companies, rising number of clinical trials due to lower operating costs, and favorable regulatory policies in place. According to the EFPIA report published in 2023, R&D expenditure by pharmaceutical companies in China grew from US$ 10,814.23 million in 2020 to US$ 12,989.23 million in 2021. China has the world's second-largest pharmaceutical market. The excessive population in the country, coupled with a rise in the cases of various noncommunicable and infectious diseases, fuels the need for new drug molecules, which makes China a prime market in Asia Pacific.
Asia Pacific Pharmacokinetics Services Market Revenue and Forecast to 2031 (US$ Million)
Asia Pacific Pharmacokinetics Services Market Segmentation
The Asia Pacific pharmacokinetics services market is categorized into drug type, service type, therapeutic application, end user, and country.
Based on drug type, the Asia Pacific pharmacokinetics services market is segmented small molecule, large molecule, and vaccines. The small molecule segment held the largest market share in 2023.
In terms of service type, the Asia Pacific pharmacokinetics services market is categorized into pre-clinical ADME and human studies, PK/PD analysis and reporting, dosing simulations, risk analysis, and others. The pre-clinical ADME and human studies segment held the largest market share in 2023.
By therapeutic application, the Asia Pacific pharmacokinetics services market is segmented into oncology, infectious diseases, neurological disorders, autoimmune diseases, gynaecological disorders, cardiovascular diseases, respiratory disorders, and others. The oncology segment held the largest market share in 2023.
By end user, the Asia Pacific pharmacokinetics services market is segmented into pharmaceutical and biotechnology companies, contract research organization, and others. The contract research organization segment held the largest market share in 2023.
By country, the Asia Pacific pharmacokinetics services market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. Japan dominated the Asia Pacific pharmacokinetics services market share in 2023.
Allucent; Certara Inc.; Charles River Laboratories International Inc; Eurofins Scientific SE; PACIFIC BIOLABS; Parexel International Corp; SGS SA; Shanghai Medicilon Inc.; and Thermo Fisher Scientific Inc. are some of the leading companies operating in the Asia Pacific pharmacokinetics services market.
Table Of Contents
1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Asia Pacific Pharmacokinetics Services Market - Key Market Dynamics
4.1 Market Drivers
4.1.1 Rising Prevalence of Chronic and Infectious Diseases
4.1.2 Expanding Range of Application of Pharmacokinetic Studies
4.1.3 Outsourcing of Pharmacokinetics Services to CROs
4.2 Market Restraints
4.2.1 Limited Reach of Pharmacokinetics Service Providers in Emerging Countries
4.3 Market Opportunities
4.3.1 Increasing Adoption of In-Vivo and In-Vitro Models for Understanding Variability in Pharmacokinetics
4.4 Future Trend
4.4.1 Increasing Adoption of Big Data Analytics in Pharmacokinetics Services
4.5 Impact of Drivers and Restraints:
5. Pharmacokinetics Services Market - Asia Pacific Analysis
5.1 Asia Pacific Pharmacokinetics Services Market Overview
5.2 Asia Pacific Pharmacokinetics Services Market Revenue (US$ Million), 2021-2031
6. Asia Pacific Pharmacokinetics Services Market Analysis - by Drug Type
6.1 Overview
6.2 Small Molecule
6.2.1 Overview
6.2.2 Small Molecule: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
6.3 Large Molecule
6.3.1 Overview
6.3.2 Large Molecule: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
6.4 Vaccines
6.4.1 Overview
6.4.2 Vaccines: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
7. Asia Pacific Pharmacokinetics Services Market Analysis - by Service Type
7.1 Overview
7.2 Pre-Clinical ADME and Human Studies
7.2.1 Overview
7.2.2 Pre-Clinical ADME and Human Studies: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
7.3 PK/PD Analysis and Reporting
7.3.1 Overview
7.3.2 PK/PD Analysis and Reporting: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
7.4 Dosing Simulations
7.4.1 Overview
7.4.2 Dosing Simulations: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
7.5 Risk Analysis
7.5.1 Overview
7.5.2 Risk Analysis: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
7.6 Others
7.6.1 Overview
7.6.2 Others: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8. Asia Pacific Pharmacokinetics Services Market Analysis - by Therapeutic Application
8.1 Oncology
8.1.1 Overview
8.1.2 Oncology: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.2 Infectious Diseases
8.2.1 Overview
8.2.2 Infectious Diseases: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.3 Neurological Disorders
8.3.1 Overview
8.3.2 Neurological Disorders: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.4 Autoimmune Diseases
8.4.1 Overview
8.4.2 Autoimmune Diseases: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.5 Gynecological Disorders
8.5.1 Overview
8.5.2 Gynecological Disorders: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.6 Cardiovascular Diseases
8.6.1 Overview
8.6.2 Cardiovascular Diseases: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.7 Respiratory Disorders
8.7.1 Overview
8.7.2 Respiratory Disorders: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.8 Others
8.8.1 Overview
8.8.2 Others: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
9. Asia Pacific Pharmacokinetics Services Market Analysis - by End User
9.1 Pharmaceutical and Biotechnology Companies
9.1.1 Overview
9.1.2 Pharmaceutical and Biotechnology Companies: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
9.2 Contract Research Organization
9.2.1 Overview
9.2.2 Contract Research Organization: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
9.3 Others
9.3.1 Overview
9.3.2 Others: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10. Asia Pacific Pharmacokinetics Services Market - Country Analysis
10.1 Asia Pacific
10.1.1 Asia Pacific Pharmacokinetics Services Market Breakdown, by Key Countries, 2023 and 2031 (%)
10.1.1.1 China: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.1.1 Overview
10.1.1.1.2 China: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.1.3 China: Asia Pacific Pharmacokinetics Services Market Breakdown, by Drug Type
10.1.1.1.4 China: Asia Pacific Pharmacokinetics Services Market Breakdown, by Service Type
10.1.1.1.5 China: Asia Pacific Pharmacokinetics Services Market Breakdown, by Therapeutic Application
10.1.1.1.6 China: Asia Pacific Pharmacokinetics Services Market Breakdown, by End User
10.1.1.2 Japan: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.2.1 Overview
10.1.1.2.2 Japan: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.2.3 Japan: Asia Pacific Pharmacokinetics Services Market Breakdown, by Drug Type
10.1.1.2.4 Japan: Asia Pacific Pharmacokinetics Services Market Breakdown, by Service Type
10.1.1.2.5 Japan: Asia Pacific Pharmacokinetics Services Market Breakdown, by Therapeutic Application
10.1.1.2.6 Japan: Asia Pacific Pharmacokinetics Services Market Breakdown, by End User
10.1.1.3 India: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.3.1 Overview
10.1.1.3.2 India: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.3.3 India: Asia Pacific Pharmacokinetics Services Market Breakdown, by Drug Type
10.1.1.3.4 India: Asia Pacific Pharmacokinetics Services Market Breakdown, by Service Type
10.1.1.3.5 India: Asia Pacific Pharmacokinetics Services Market Breakdown, by Therapeutic Application
10.1.1.3.6 India: Asia Pacific Pharmacokinetics Services Market Breakdown, by End User
10.1.1.4 Australia: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.4.1 Overview
10.1.1.4.2 Australia: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.4.3 Australia: Asia Pacific Pharmacokinetics Services Market Breakdown, by Drug Type
10.1.1.4.4 Australia: Asia Pacific Pharmacokinetics Services Market Breakdown, by Service Type
10.1.1.4.5 Australia: Asia Pacific Pharmacokinetics Services Market Breakdown, by Therapeutic Application
10.1.1.4.6 Australia: Asia Pacific Pharmacokinetics Services Market Breakdown, by End User
10.1.1.5 South Korea: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.5.1 Overview
10.1.1.5.2 South Korea: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.5.3 South Korea: Asia Pacific Pharmacokinetics Services Market Breakdown, by Drug Type
10.1.1.5.4 South Korea: Asia Pacific Pharmacokinetics Services Market Breakdown, by Service Type
10.1.1.5.5 South Korea: Asia Pacific Pharmacokinetics Services Market Breakdown, by Therapeutic Application
10.1.1.5.6 South Korea: Asia Pacific Pharmacokinetics Services Market Breakdown, by End User
10.1.1.6 Rest of Asia Pacific: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.6.1 Overview
10.1.1.6.2 Rest of Asia Pacific: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.6.3 Rest of Asia Pacific: Asia Pacific Pharmacokinetics Services Market Breakdown, by Drug Type
10.1.1.6.4 Rest of Asia Pacific: Asia Pacific Pharmacokinetics Services Market Breakdown, by Service Type
10.1.1.6.5 Rest of Asia Pacific: Asia Pacific Pharmacokinetics Services Market Breakdown, by Therapeutic Application
10.1.1.6.6 Rest of Asia Pacific: Asia Pacific Pharmacokinetics Services Market Breakdown, by End User
11. Company Profile
11.1 Charles River Laboratories International Inc
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 Eurofins Scientific SE
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 Certara Inc.
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.4 Parexel International Corp
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.4.6 Key Developments
11.5 Thermo Fisher Scientific Inc.
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments
11.6 Allucent
11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Products and Services
11.6.4 Financial Overview
11.6.5 SWOT Analysis
11.6.6 Key Developments
11.7 PACIFIC BIOLABS
11.7.1 Key Facts
11.7.2 Business Description
11.7.3 Products and Services
11.7.4 Financial Overview
11.7.5 SWOT Analysis
11.7.6 Key Developments
11.8 SGS SA
11.8.1 Key Facts
11.8.2 Business Description
11.8.3 Products and Services
11.8.4 Financial Overview
11.8.5 SWOT Analysis
11.8.6 Key Developments
11.9 Shanghai Medicilon Inc.
11.9.1 Key Facts
11.9.2 Business Description
11.9.3 Products and Services
11.9.4 Financial Overview
11.9.5 SWOT Analysis
11.9.6 Key Developments
12. Appendix
12.1 About The Insight Partners
12.2 Glossary of Terms for Pharmacokinetic Services Market
